Indaptus Therapeutics Inc (INDP)vsVertex Pharmaceuticals Inc (VRTX)
INDP
Indaptus Therapeutics Inc
$3.45
+8.83%
HEALTHCARE · Cap: $439.70M
VRTX
Vertex Pharmaceuticals Inc
$537.79
-0.15%
HEALTHCARE · Cap: $137.57B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 30.7% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 58/100 (C).
INDP
Avoid17
out of 100
Grade: F
VRTX
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INDP.
Margin of Safety
+44.9%
Fair Value
$977.14
Current Price
$537.79
$439.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 37.8%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 39.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : INDP
INDP has a balanced fundamental profile.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 30.7% and operating margin at 37.8%. Revenue growth of 11.8% demonstrates continued momentum.
Bear Case : INDP
The primary concerns for INDP are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
INDP profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
INDP carries more volatility with a beta of 0.94 — expect wider price swings.
VRTX is growing revenue faster at 11.8% — sustainability is the question.
VRTX generates stronger free cash flow (546M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (58/100 vs 17/100), backed by strong 30.7% margins and 11.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Indaptus Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms. Utilizing its proprietary platform, the company enhances the immune system's capacity to identify and eliminate tumor cells, thereby improving therapeutic efficacy and patient outcomes. With a robust pipeline of clinical candidates aimed at addressing critical unmet needs in oncology, Indaptus is strategically positioned for growth in a competitive market. By fostering collaborations with leading research institutions and a commitment to scientific innovation, Indaptus aspires to emerge as a key player in the biopharmaceutical sector.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?